{"id":"NCT02214225","sponsor":"Seqirus","briefTitle":"A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.","officialTitle":"A Phase 3, Randomized, Multicenter, Double-blinded Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (CSL QIV) in Comparison With a US Licensed 2014/2015 Trivalent Influenza Vaccine (CSL TIV-1), and a Trivalent Influenza Vaccine Containing the Alternate B Strain (CSL TIV-2), in Adults Aged 18 Years and Above.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-08","primaryCompletion":"2014-11","completion":"2015-04","firstPosted":"2014-08-12","resultsPosted":"2016-02-23","lastUpdate":"2017-03-13"},"enrollment":3484,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza, Human"],"interventions":[{"type":"BIOLOGICAL","name":"Quadrivalent Influenza Vaccine (QIV)","otherNames":[]},{"type":"BIOLOGICAL","name":"Trivalent Influenza Vaccine (TIV-1)","otherNames":[]},{"type":"BIOLOGICAL","name":"Trivalent Influenza Vaccine (TIV-2)","otherNames":[]}],"arms":[{"label":"Quadrivalent Influenza Vaccine (QIV)","type":"EXPERIMENTAL"},{"label":"Trivalent Influenza Vaccine (TIV-1)","type":"ACTIVE_COMPARATOR"},{"label":"Trivalent Influenza Vaccine (TIV-2)","type":"ACTIVE_COMPARATOR"}],"summary":"This is a study to assess the immune (antibody) response and safety of a bioCSL split virion, inactivated quadrivalent influenza vaccine, in comparison with a US licensed 2014/2015 trivalent influenza vaccine (bioCSL TIV-1), and a trivalent influenza vaccine containing the alternate B strain (bioCSL TIV-2), in healthy adult volunteers aged 18 years and above.","primaryOutcome":{"measure":"Postvaccination Geometric Mean Titer (GMT) (Statistical Analysis: GMT Ratios) in Subjects Aged â‰¥18 Years (Per Protocol Population).","timeFrame":"21 days after vaccination.","effectByArm":[{"arm":"GMT: bioCSL QIV","deltaMin":303,"sd":null},{"arm":"GMT: Pooled TIV (A Strains) or TIV-1 (B/YAM) or TIV-2 (B/VIC)","deltaMin":280.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":6},"locations":{"siteCount":33,"countries":["United States"]},"refs":{"pmids":["28302411"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":39,"n":1721},"commonTop":["Pain","Myalgia","Headache","Malaise"]}}